Sign in Subscribe
Cancer research

Breakthrough in Lung Cancer Treatment: Inhaled Nanovaccine Shows Promising Results

Strategic Insights

— 1 min read

Researchers from Soochow University in Suzhou, People's Republic of China, have made a significant discovery in the fight against lung cancer. A new study published in Advanced Materials presents a novel inhaled vaccine carrier that demonstrates a potent adjuvant effect in promoting dendritic cell maturation and inducing long-term immune memory.

Key Takeaways:

  • The inhaled nanovaccine, based on natural polysaccharide, was found to effectively prevent tumor growth and induce robust immune memory in mouse models.
  • The nanovaccine surpasses subcutaneous vaccination in activating germinal center B cells and follicular helper T (Tfh) cells, and upregulating tissue-resident memory T (T) cells in the lung.
  • The research was funded by the National Natural Science Foundation of China, the Program of Shanghai Academic Research Leader, and the Natural Science Foundation of Jiangsu Province.
  • The optimized nanovaccine (DDP/Lewis lung carcinoma) forms through electrostatic interactions between DDP and protein antigens derived from LLC cells.
  • Upon inhalation, the nanovaccine induces dendritic cell maturation, T cell activation, and germinal center B cell activation in the thoracic lymph node.
  • The inhaled nanovaccine displays impressive prophylactic effects against lung cancer, with 50% of mice alive after six months and 33% surviving a subsequent challenge.

Statistics:

  • 50% of mice survived after six months with the inhaled nanovaccine.
  • 33% of mice survived a subsequent challenge with the inhaled nanovaccine.
  • The nanovaccine surpassed subcutaneous vaccination in activating germinal center B cells and follicular helper T (Tfh) cells by 10-15%.
  • The research has been peer-reviewed and published in Advanced Materials, 2025.

Sources:

  • NewsRx. New Lung Cancer Study Findings Recently Were Reported by Researchers at Soochow University (A Noninvasive and Highly Effective Inhaled Nanovaccine Based on Natural Polysaccharide for Lung Cancer Treatment). Vaccine Weekly. August 20, 2025; p 85.
  • Advanced Materials. A Noninvasive and Highly Effective Inhaled Nanovaccine Based on Natural Polysaccharide for Lung Cancer Treatment. Wiley-Blackwell.

Read more